Italian pharmaceutical giant Recordati is currently in deliberations regarding a significant acquisition offer from global private equity firm CVC Capital Partners. The proposed deal, which would see CVC acquire the remaining 48.2% stake in Recordati not already held by the firm, values the company at an impressive €10.9 billion (approximately $12.6 billion). If Recordati’s board accepts CVC’s proposal, the landmark transaction would necessitate the delisting of Recordati from the Italian Stock Exchange, marking a pivotal shift in its corporate structure and public market presence.
The offer from CVC, amounting to €52 per share, aims to consolidate CVC’s controlling interest in Recordati, a company with a rich history spanning a century. This move follows CVC’s initial significant investment in 2018, when the private equity firm acquired a 51.8% controlling stake in Recordati for €3.03 billion. The current offer represents a substantial premium and a strategic culmination of CVC’s long-term vision for the pharmaceutical group.
While Recordati has publicly acknowledged that its corporate bodies have "not yet reviewed the indication of interest within its corporate bodies," the confirmation of the ongoing discussions has sent ripples through the financial and pharmaceutical sectors. The potential delisting signifies a transition from a publicly traded entity to a privately held company, which could offer Recordati greater strategic flexibility and long-term investment horizons, free from the quarterly pressures of public market scrutiny.
A Century of Pharmaceutical Innovation: Recordati’s Legacy
Recordati, a company celebrating its 100th anniversary this year, has established itself as a global pharmaceutical group with a diversified portfolio focused on primary and secondary care, as well as a strong commitment to addressing rare diseases. Its therapeutic areas of expertise include haematological oncology, endocrinology, and metabolic health, underscoring its dedication to tackling complex and often underserved medical conditions.
The company’s product pipeline boasts several key therapies, including its highly successful Cushing’s disease treatment, Isturisa (osilodrostat). Analyst consensus projections from GlobalData indicate that Isturisa is poised for significant commercial success, with estimated sales reaching $967 million by 2031. This robust performance highlights Recordati’s capability in developing and commercializing innovative treatments for niche indications.
In a significant recent expansion of its rare disease portfolio, Recordati acquired the global rights to Enjaymo (sutimlimab), a medicine for cold agglutinin disease (CAD), from Sanofi. This strategic acquisition, completed in 2024 for an upfront payment of $825 million, further solidifies Recordati’s position in the rare disease market and diversifies its revenue streams.
Beyond its established therapies, Recordati is also actively engaged in cutting-edge research and development. The company has forged a strategic partnership with mRNA specialist Moderna to develop a novel therapy for propionic acidaemia, mRNA-3927. This investigational therapy is currently progressing through global Phase I/II trials, signaling Recordati’s commitment to exploring advanced therapeutic modalities for rare metabolic disorders.
Financial Fortitude Amidst Strategic Realignments
Recordati’s financial performance in recent periods has been notably strong, providing a solid foundation for its current strategic considerations. In 2025, the company reported an impressive 11.8% increase in net revenue, reaching €2.6 billion. This growth was largely propelled by the exceptional performance of its rare disease segment, which experienced a substantial 29.7% surge in revenues compared to the previous year. This financial resilience underscores the company’s operational strength and the increasing market demand for its specialized therapies.
The Broader Landscape of Pharmaceutical M&A
CVC’s proposed takeover bid for Recordati arrives at a dynamic juncture for the pharmaceutical industry, characterized by a surge in mergers and acquisitions (M&A). Companies are actively seeking to bolster their pipelines and mitigate the impact of impending patent expirations by acquiring innovative assets and complementary businesses.
In a significant development on March 27th, Novartis announced its intention to acquire Expericell for up to $3 billion. This acquisition will integrate Expericell’s half-life extended, high-affinity anti-IgE antibody, EXL-111, currently in Phase I clinical trials, into Novartis’s portfolio.
Earlier in the week, MSD (Merck & Co.) made a substantial investment of $6.7 billion to acquire Terns Pharmaceuticals. This move is widely seen as a strategic effort to reinforce MSD’s oncology pipeline, particularly with Terns’ lead asset, TERN-701, a BCR-ABL1 tyrosine kinase inhibitor (TKI). Some industry analysts have suggested that the valuation of this deal may not fully reflect the long-term potential of TERN-701.
On March 24th, Gilead Sciences signaled its entry into the T-cell engager (TCE) market with a $2.2 billion acquisition of Ouro Medicines. This deal also opens the possibility of a co-development partnership with Galapagos for Ouro’s lead asset, gamgertamig, further expanding Gilead’s therapeutic reach.
Analysis from GlobalData, the parent company of Pharmaceutical Technology, indicates a significant uptick in pharmaceutical M&A deal value in 2025 year-to-date. This trend suggests a renewed sense of optimism within the sector, with acquirers exhibiting a more selective approach, focusing their investments on a smaller number of high-value transactions that promise substantial strategic returns.
Potential Implications of a CVC Takeover
The potential delisting of Recordati from the Italian Stock Exchange under CVC’s ownership would have several significant implications. For CVC, it represents the consolidation of a substantial investment and the opportunity to steer Recordati’s strategic direction without the immediate pressures of public market reporting and shareholder demands. This could allow for longer-term strategic investments in R&D, pipeline expansion, and market penetration, potentially accelerating Recordati’s growth trajectory.
For Recordati’s employees and management, the transition to a private entity could lead to a shift in operational focus. While public companies are beholden to quarterly earnings reports and investor expectations, private companies often have more flexibility to pursue long-term strategic goals, potentially involving significant capital investments or restructuring.
For investors who remain with Recordati or are considering the offer, the €52 per share valuation represents a significant opportunity to realize substantial returns on their investment. The offer price reflects a premium over recent trading prices, indicating CVC’s strong conviction in Recordati’s future value.
The delisting would also mean the end of Recordati’s public trading history on the Borsa Italiana. This could impact liquidity for existing shareholders who may wish to divest their holdings, although the terms of the offer would typically provide clear pathways for shareholders to tender their shares.
The move also aligns with a broader trend of private equity firms actively investing in the pharmaceutical and biotechnology sectors, drawn by the sector’s robust growth potential, innovation pipeline, and the increasing demand for specialized healthcare solutions. CVC’s long-standing relationship with Recordati, initiated in 2018, suggests a deep understanding of the company’s assets, market position, and future prospects.
As Recordati’s board deliberates on CVC’s substantial offer, the pharmaceutical industry will be closely watching the outcome of this potential landmark transaction. The decision will not only shape the future of Recordati but also contribute to the ongoing narrative of consolidation and strategic repositioning within the global pharmaceutical landscape. The potential delisting signals a new chapter for the century-old company, one that could be defined by accelerated growth and strategic maneuverability under private ownership.
Leave a Reply